Flavopiridol National Cancer Institute

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1149-1155

  Wang, H K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; L 868276; NSC 649980;

ANOREXIA; CLINICAL TRIAL; COLON CANCER; COLON TUMOR; DIARRHEA; DOSE RESPONSE; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME INHIBITION; ESOPHAGUS TUMOR; FATIGUE; HEART INFARCTION; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; REVIEW; SOLID TUMOR; STOMACH TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FLAVONOIDS; HUMANS; NEOPLASMS; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034868715     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
2. Preclinical studies with L86-8275 (flavopiridol), an antagonist of cyclin dependent protein kinases
3. L86-8275, a new flavone with selectivity in prostate cancer in vitro and in vivo
4. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
5. Alteration of the phosphorylation state of p34 (cdc2) kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity
6. Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms
7. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
8. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
9. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
10. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
11. Trials underway, flavopiridol
12. Potentiation of apoptosis by flavopiridol in mitomycin C-treated gastric and breast cancer cells
13. Hoechst - Stripped to its core
14. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
15. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
16. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
17. Flavopiridol has marked in vitro activity against human B-chronic lymphocytic leukemia (B-CLL) and induces apoptosis independent of p53 status
18. The cyclin-dependent kinase inhibitor, flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
19. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
20. Clinical trials referral resource. Clinical trials of flavopiridol
21. Cell cycle-independent induction of apoptosis by the antitumor drug flavopiridol in endothelial cells
22. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
23. Therapy of chronic lymphocytic leukemia: It is time to move on to the next important question
24. ABN AMRO: Pan-Europe Pharmaceuticals: Pan-European Pharmaceutical Review
25. Flavopiridol
26. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
27. Pipeline products, phase I, II, III
28. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
29. Merrill Lynch: Pharmaceutical Models: Europe
30. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects
31. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
32. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
33. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
34. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
35. Merrill Lynch: Aventis: Improving quality and quantity
36. The Cancer Institute of New Jersey. Active clinical trials as of 12/14/2000
37. A phase IB clinical trial of the sequence dependent combination of paclitaxel (P) and cisplatin (C) with the cyclin dependant kinase (CDK) inhibitor flavopiridol in patients with advanced solid tumors
38. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
39. Aventis Pharma R&D Day, London, May 15, 2001
40. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
41. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
42. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
43. Potent interaction of flavopiridol with MRP1
44. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
45. Effect of P-glycoprotein on flavopiridol sensitivity
46. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells
47. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of UDP-glucuronosyltransferases 1A1 and 1A9
48. Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol
49. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells
50. Evaluation of intravenous flavopiridol formulations
51. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status
52. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein
53. Structure activity relationship studies of flavopiridol analogues
54. The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Meliaceae)
55. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results